ALK-positive non-small cell lung cancer (NSCLC) is a subtype of lung cancer characterised by a genetic mutation in the anaplastic lymphoma kinase (ALK) gene. Several first-line treatments are available

One of the most common and fatal types of cancer in the world continues to be lung cancer. The most prevalent form of lung cancer, non-small cell lung cancer (NSCLC), is characterised by its heterogeneity,

A 2020 Spanish study found CBD and THC treat the most common type of lung cancer. Non-small lung carcinomas (NSCLC) represents 85% of all lung cancers. Both canabinoid agonists (THC and CBD) alone, and

Ceritinib (trade name Zykadia ) is a prescription-only drug used for the treatment non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014. Zykadia